Drug Class Review: Newer Antiplatelet Agents: Final Report Update 1 [Internet]

Janet H Dailey; Peter Glassman; Marian McDonagh; Kim Peterson; Marika Suttorp; Susan Chen

Drug Class Review: Newer Antiplatelet Agents: Final Report Update 1 [Internet]

Review

Portland (OR): Oregon Health & Science University; 2007 Apr.

Drug Class Reviews.

Authors

Janet H Dailey¹, Peter Glassman¹, Marian McDonagh², Kim Peterson², Marika Suttorp¹, Susan Chen¹

Affiliations

¹ Southern California Evidence-based Practice Center, RAND, 1700 Main Street, PO Box 2138, Santa Monica, CA 90407, Paul Shekelle, Director
² Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director

PMID: 20495616
Bookshelf ID: NBK10384

Excerpt

Antiplatelet medications are a pharmacologic component of secondary prevention of vascular disease caused by atherosclerosis. For many years aspirin has been considered the standard agent. Newer antiplatelet agents have begun to come to the forefront as adjuncts to or substitutes for aspirin in certain clinical situations. The purpose of this review is to compare evidence of the benefits and harms of the newer antiplatelet medications clopidogrel, ticlopidine, dipyridamole, and dipyridamole ER-plus-aspirin.

Sections

Publication types

Review

Grants and funding

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.